RADIATION THERAPY ONCOLOGY GROUP
RTOG 0126
|
A PHASE III RANDOMIZED STUDY OF HIGH DOSE 3D-CRT
VERSUS STANDARD DOSE 3D-CRT IN PATIENTS TREATED FOR LOCALIZED
PROSTATE CANCER
(Closed to patient accrual as of 8/20/08.)
|
RTOG 0232
|
A PHASE III STUDY COMPARING COMBINED EXTERNAL BEAM
RADIATION AND TRANSPERINEAL INTERSTITIAL PERMANENT BRACHYTHERAPY
WITH BRACHYTHERAPY ALONE FOR SELECTED PATIENTS WITH INTERMEDIATE
RISK PROSTATIC CARCINOMA |
NSABP B-39/
RTOG 0413
|
A RANDOMIZED PHASE III STUDY
OF CONVENTIONAL WHOLE BREAST IRRADIATION (WBI)
VERSUS PARTIAL BREAST IRRADIATION (PBI)
FOR WOMEN WITH STAGE 0, I, OR II BREAST CANCER |
|
A PHASE III RANDOMIZED STUDY OF HYPOFRACTIONATED
3D-CRT/IMRT VERSUS CONVENTIONALLY FRACTIONATED
3D-CRT/IMRT IN PATIENTS WITH FAVORABLE-RISK PROSTATE CANCER
|
|
A PHASE II STUDY OF AN ORAL EPIDERMAL GROWTH FACTOR
RECEPTOR TYROSINE KINASE INHIBITOR (EGFR TKI) ZD 1839
(IRESSA(r)) IN COMBINATION WITH
DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY
IN UNTREATED PATIENTS WITH LOCALLY ADVANCED
CERVICAL CARCINOMA
|
|
A PHASE II STUDY OF INTENSITY MODULATED RADIATION
THERAPY (IMRT) TO THE PELVIS +/- CHEMOTHERAPY FOR
POST-OPERATIVE PATIENTS WITH EITHER ENDOMETRIAL OR
CERVICAL CARCINOMA
|
|
A PHASE III TRIAL EVALUATING THE ADDITION OF CETUXIMAB TO
PACLITAXEL, CISPLATIN, AND RADIATION FOR PATIENTS WITH
ESOPHAGEAL CANCER WHO ARE TREATED WITHOUT SURGERY
|
|
A PHASE I TRIAL OF HIGHLY CONFORMAL
RADIATION THERAPY FOR PATIENTS WITH LIVER METASTASES
|
|
A PHASE III PROTOCOL OF ANDROGEN SUPPRESSION (AS) AND
3DCRT/IMRT VS. AS AND 3DCRT/IMRT FOLLOWED BY
CHEMOTHERAPY WITH DOCETAXEL AND PREDNISONE
FOR LOCALIZED, HIGH-RISK PROSTATE CANCER
|
|
A RANDOMIZED PHASE III TRIAL OF CONCURRENT ACCELERATED
RADIATION AND CISPLATIN VERSUS CONCURRENT ACCELERATED
RADIATION, CISPLATIN, AND CETUXIMAB (C225)
[FOLLOWED BY SURGERY FOR SELECTED PATIENTS]
FOR STAGE III AND IV HEAD AND NECK CARCINOMAS
|
|
A PROSPECTIVE PHASE II TRIAL OF TRANSPERINEAL
ULTRASOUND-GUIDED BRACHYTHERAPY FOR LOCALLY RECURRENT
PROSTATE ADENOCARCINOMA FOLLOWING EXTERNAL BEAM
RADIOTHERAPY
|
|
A PHASE III TRIAL OF SHORT TERM ANDROGEN DEPRIVATION WITH
PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPORT)
IN PROSTATE CANCER PATIENTS WITH A RISING PSA AFTER RADICAL
PROSTATECTOMY
|
|
PHASE II TRIAL OF OBSERVATION FOR LOW-RISK MENINGIOMAS AND OF RADIOTHERAPY FOR INTERMEDIATE- AND HIGH-RISK MENINGIOMAS
|
|
A PHASE II STUDY OF CONCURRENT CHEMORADIOTHERAPY USING THREE-DIMENSIONAl
CONFORMAL RADIOTHERAPY (3D CRT) OR INTENSITY-MODULATED RADIATION ThERAPY
(IMRT) + BEVACIZUMAB (BV) FOR LOCALLY OR REGIONALLY ADVANCED NASOPHARYNGEAL CANCER
|
|
A RANDOMIZED PHASE III COMPARISON OF STANDARD-DOSE (60 Gy)
VERSUS HIGHDOSE (74 Gy) CONFORMAL RADIOTHERAPY WITH CONCURRENT
AND CONSOLIDATION CARBOPLATIN/PACLITAXEL +/- CETUXIMAB
(IND #103444) IN PATIENTS WITH STAGE IIIA/IIIB
NON-SMALL CELL LUNG CANCER |
|
A PHASE II TRIAL OF STEREOTACTIC BODY RADIATION THERAPY (SBRT)
IN THE TREATMENT OF PATIENTS WITH OPERABLE STAGE I/II
NON-SMALL CELL LUNG CANCER
|
|
A RANDOMIZED PHASE II TRIAL OF CHEMORADIOTHERAPY
VERSUS CHEMORADIOTHERAPY AND VANDETANIB FOR HIGH-RISK
POSTOPERATIVE ADVANCED SQUAMOUS CELL CARCINOMA
OF THE HEAD AND NECK
|
|
ADJUVANT 3DCRT/IMRT IN COMBINATION WITH ANDROGEN SUPPRESSION
AND DOCETAXEL FOR HIGH RISK PROSTATE CANCER PATIENTS
POST-PROSTATECTOMY: A PHASE II TRIAL
|
|
A PHASE I/II TRIAL OF SAMARIUM-153 FOLLOWED BY SALVAGE PROSTATIC FOSSA
IRRADIATION IN HIGH-RISK, CLINICALLY NON-METASTATIC PROSTATE CANCER
AFTER RADICAL PROSTATECTOMY
|
|
A PHASE II TRIAL OF COMBINED MODALITY THERAPY WITH GROWTH FACTOR
SUPPORT FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER
|
|
A PHASE II TRIAL OF IMAGE GUIDED PREOPERATIVE RADIOTHERAPY
FOR PRIMARY SOFT TISSUE SARCOMAS OF THE EXTREMITY
|
|
PHASE II/III STUDY OF IMAGE-GUIDED RADIOSURGERY/SBRT
FOR LOCALIZED SPINE METASTASIS
|
|
A PHASE II RANDOMIZED STUDY FOR PATIENTS WITH MUSCLE-INVASIVE
BLADDER CANCER EVALUATING TRANSURETHRAL SURGERY AND CONCOMITANT
CHEMORADIATION BY EITHER BID IRRADIATION PLUS 5-FLOUROURACIL
AND CISPLATIN OR QD IRRADIATION PLUS GEMCITABINE FOLLOWED BY
SELECTIVE BLADDER PRESERVATION AND GEMCITABINE/CISPLATIN
ADJUVANT CHEMOTHERAPY
|
|
PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY
|
|
SEAMLESS PHASE I/II STUDY OF STEREOTACTIC LUNG RADIOTHERAPY (SBRT)
FOR EARLY STAGE, CENTRALLY LOCATED,
NON-SMALL CELL LUNG CANCER (NSCLC) IN MEDICALLY INOPERABLE PATIENTS
|
|
A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER
|
|
A PHASE II EVALUATION OF PREOPERATIVE CHEMORADIOTHERAPY
UTILIZING INTENSITY MODULATED RADIATION THERAPY (IMRT)
IN COMBINATION WITH CAPECITABINE AND OXALIPLATIN FOR
PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
|
|
PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS BEVACIZUMAB VERSUS CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
|
|
A RANDOMIZED PHASE II STUDY COMPARING 2 STEREOTACTIC BODY RADIATION THERAPY (SBRT) SCHEDULES FOR MEDICALLY INOPERABLE PATIENTS WITH STAGE I PERIPHERAL NON-SMALL CELL LUNG CANCER
|
|
A PHASE III STUDY OF POSTOPERATIVE RADIATION THERAPY (IMRT) +/- CETUXIMAB
FOR LOCALLY-ADVANCED RESECTED HEAD AND NECK CANCER
|
|
|
